Download now: The Downfall of Cable, and the Rise of 5G!

FDA Approval Sets up Biotech Market for Success

Written by Monica Savaglia
Posted August 24, 2021

On Monday, the U.S. Food and Drug Administration (FDA) gave its full approval to the Pfizer (NYSE: PFE)/BioNTech (NASDAQ: BNTX) COVID-19 vaccine for people age 16 and older. 

This is the first coronavirus vaccine approval from the FDA, and it could easily create a path for other COVID-19 vaccine approvals. The approval could also result in more vaccine mandates throughout the country. Earlier this week, the FDA's website said the following:

Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 vaccine, and will now be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older.

The vaccine received emergency-use approval last year in mid-December for people age 16 and older, as the coronavirus pandemic was prevalent throughout the country and there was no way of containing outbreaks that were occurring. Then in May, as the vaccine was being rolled out to the majority of the public, the emergency-use authorization was extended so that people age 12 and older could have access to the vaccines as well. 

In this week's announcement from the FDA, the organization reiterated this:

The vaccine also continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.

FDA Approval Could Mean Increase of Vaccine Requirements

About 170 million people in the U.S. have been fully vaccinated against COVID-19, and more than 92 million have received the Pfizer/BioNTech vaccine. This recent approval from the FDA could increase vaccination numbers, especially as more businesses and universities have been holding off on requiring vaccines for customers, employees, students, and faculty. 

U.S. Surgeon General Dr. Vivek Murthy said this during an interview earlier in the week:

For businesses and universities that have been thinking about putting vaccine requirements in place in order to create safer spaces for people to work and learn, I think that this move from the FDA, when it comes, will actually help them to move forward with those kinds of plans. 

Well, the decision is here, and we can expect to see more places requiring people to be vaccinated. 

Many medical professionals along with the Biden administration are hoping that this approval from the FDA for the COVID-19 vaccines will bring more confidence to the public so that the coronavirus cases and hospitalizations can begin to decrease again and we can leave this pandemic in the past. 

Paving the Way for a Robust Biotech Market

On the news of the FDA’s approval of the Pfizer/BioNTech vaccine, BioNTech surged 7.7%. The approval of COVID-19 vaccines for emergency use and now full approval for the Pfizer/BioNTech vaccine has paved the way for a strong biotech market, not just for COVID-19 vaccines and treatments, but also for other various diseases that have been without a cure or treatment for a while. The breakthrough of COVID-19 vaccines being developed and how quickly they were able to be delivered to people during a desperate time has increased optimism that there could be treatments that can come to market a lot sooner than they have in the past.

The technology that was involved in creating the vaccines could have the potential to help fight other ailments like cancer and malaria. Earlier this month, BioNTech shares rallied after the company told its investors on its earnings call that it has plans to push forward human trials for flu, malaria vaccines, and cancer treatments using messenger RNA technology.

According to Investor's Business Daily, BioNTech reported $6.24 billion in its second-quarter sales — beating analysts' expectations, which had sales estimated at around $3.83 million. Data from MarketWatch has indicated that BioNTech shares have increased by 422% since the beginning of 2021 and Moderna has been up by around 333%. 

These are the kind of gains that every investor hopes to experience in their lifetime. Well, for some, that hope has the possibility to become reality, especially for those who know how to navigate the biotech market. You just need the right tools in your pocket.

Without a doubt, the global biotechnology market is set to go big in the years to come. It’s just a matter of understanding what these companies are working on and when their products could hit the market. 

Some people think that the tools and resources that give you all the information to set you up for once-in-a-lifetime gains aren't accessible to them. However, that’s not true. 

My colleague Keith Kohl has been working closely with an investment strategy that gives everyday investors the chance to bank six triple-digit winners every month. It’s a unique system that doesn’t discriminate. You don’t need a Ph.D. or even a college education. This strategy gives investors the chance to be a part of one of the hottest sectors in the market — biotechnology.

If you want to be a part of the $1.1 trillion biotech market or want to know more about this groundbreaking investment system, click here to meet Keith. He'll give you all the details about this system along with much more information about the biotech sector.

Until next time,

Monica Savaglia Signature Park Avenue Digest

Monica Savaglia

Monica Savaglia is Wealth Daily’s IPO specialist. With passion and knowledge, she wants to open up the world of IPOs and their long-term potential to everyday investors. She does this through her newsletter IPO Authority, a one-stop resource for everything IPO. She also contributes regularly to the Wealth Daily e-letter. To learn more about Monica, click here.

Buffett's Envy: 50% Annual Returns, Guaranteed